With the popular social media app once again at risk of going dark, there are best practices pharma brands can use on other ...

Deutsche Bank says Biohaven’s (BHVN) competitor Immunovant (IMVT) reported topline data for FcRn antibody batoclimab in myasthenia gravis and ...

To tackle the inequity in medication access, a societal issue especially in developing nations, a team of undergraduate student-researchers at the University of Ottawa has developed a new ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) today and set a price target of ...

HC Wainwright reissued their buy rating on shares of Biohaven (NYSE:BHVN – Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $54.00 price target on the stock.

DUBLIN and DURHAM, N.C., March 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix ...

Biohaven Ltd. (BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat... ByInvesting ...

Today, a brief rundown of news involving Acelyrin and Neumora Therapeutics, as well as updates from Biohaven, Lexicon Pharmaceuticals and Pliant Therapeutics you may have missed. Shares of Lexicon ...

Biohaven acquired BHV-7000 as part of a February 2022 buyout of Channel Biosciences. Image credit: Shutterstock / ma_Design. Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody ...